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Ruthenium–arene complexes with NSAIDs:
synthesis, characterization and bioactivity†
Ana Tadic´,a Jelena Poljarevic´, *a Milena Krstic´, b Marijana Kajzerberger,c
Sandra Arand-elovic´,c Sinisˇa Radulovic´, c Chrisoula Kakoulidou, d
Athanasios N. Papadopoulos, e George Psomas d and Sanja Grguric´-Sˇipka *a
Two non-steroidal antiinflammatory drugs indomethacin and mefenamic acid were coordinated to
Ru(II)–arenes to afford four new complexes. The cytotoxic activities of the ligands and ruthenium complexes
were tested in three human cancer cell lines (K562, A549, MDA-MB-231) and non-tumour human fetal
lung fibroblast cells (MRC-5) by MTT assay. Cytotoxicity studies revealed that indomethacin Ru(II)–arene
complexes 1 and 3 displayed good cytotoxicity and apparent cytoselective profiles. The IC50 values obtained
in leukemia K562 cells were comparable to those of cisplatin (10.3 mM (CDDP), 11.9 mM (1) and 13.2 mM (3)).
Flow cytometric analysis of 1 and 3 in triple-negative breast cancer MDA-MB-231 cells revealed an
interesting mechanism of action. At IC50 concentrations, 1 and 3 arrested cell cycle progression in S phase
and caused rapid accumulation of cells in sub-G1 phase (up to 48%), while Annexin V-FITC/PI staining
showed simultaneous occurrence of apoptotic and necrotic cell populations at approximately similar levels
of 20%. Measurement of reactive oxygen species (ROS) production by DCFH-DA staining confirmed
the potential of 1 and 3 to increase ROS even more than cisplatin. The interaction of the complexes with
serum albumins showed their potential ability to bind tightly and reversibly to albumins. The affinity of the
complexes to calf-thymus DNA was investigated by UV-vis spectroscopy, viscosity measurements and
fluorescence emission spectroscopy for competitive studies of the complexes with ethidium bromide,
revealing that their interaction probably occurs via intercalation. Taken together, the results strongly suggest
the potential of complexes 1 and 3 to alter cell cycle progression and cause DNA-damage by means of
direct DNA-binding or indirectly by ROS production.
Introduction
Rosenberg’s highly significant discovery of cisplatin1 opened
the way for the introduction of metal complexes in cancer
chemotherapy; since then, scientists have been searching for
new potential anticancer compounds. Currently, research in
that field is focused on ruthenium(II) complexes.2 Ruthenium
complexes have been investigated for use as DNA topoisomerase
inhibitors,3 TrxR inhibitors,4 antimicrobial agents,5 molecular
probes6 and anticancer agents.7 Also, ruthenium can mimic
iron in binding with certain biological molecules, particularly
transferrin, and Ru(II) and Ru(III) complexes can display similar
ligand exchange kinetics to Pt(II).8 Considering all these charac-
teristics, ruthenium complexes are suitable for medical
applications. Three of these, namely KP1339, KP1019 and NAMI,
have entered clinical trials, with promising results.2,9,10 A number
of ruthenium(II) complexes bearing p-bonded arene ligands have
already been developed and have shown promising anticancer
activities.11 Because the concentration of oxygen in tumor cells is
low, the environment is more reductive than in normal tissue,
favouring the active reduced form.8,12
A real revolution in medicine occurred with the discovery of
non-steroidal anti-inflammatory drugs (NSAIDs), which have
been proven to be biologically active compounds. NSAIDs are
one of the most commonly used classes of medication.13 Their
main mechanism of action is based on the inhibition of the
enzyme cyclooxygenase (COX), more precisely, its two isoforms:
COX-1 and COX-2. By this method, they prevent the formation
of various prostaglandins responsible for the physiological
responses of fever, pain sensation and anti-inflammation.14
Also, NSAIDs have synergistic action on the activity of certain
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antitumor drugs15 and can lead to cell death of a series of
cancer cell lines via apoptosis.16 Metal complexes containing
NSAIDs17 are among the compounds which have received much
attention and increasing interest from a medicinal inorganic
chemistry viewpoint because they are found in coordination
compounds which have active drugs as ligands.15
Indomethacin (Hindo, Fig. 1) is a phenylalkanoic acid and is
one of the most potent clinically used NSAIDs. It is used to
relive pain, fever and inflammation. Despite the known adverse
gastrointestinal side-effects (ulceration and hemorrhage) limiting
the doses and use of NSAIDs, Hindo and its Cu(II) complex are
widely safely administered in the clinical treatment of acute
inflammation and other medical conditions in humans.18
A series of copper(II)19–22 and two tin23 complexes with indo-
methacin as a ligand have been reported in the literature.
Mefenamic acid (Hmef, Fig. 1), or N-phenylanthranilic acid,
is in clinical use. Mefenamic acid is an effective analgesic and
antipyretic agent with relatively mild side-effects, including
headaches, diarrhea, vomiting and nervousness.24,25 Recently,
Cu(II),26–29 Co(II),30,31 Ni(II),32 Zn(II),33 Mn(II)34 and Sn(IV)35 complexes
with mefenamato ligands have been reported.
Recently, Hartinger and Dyson showed in separate studies
that oxicam-based NSAIDs, as well as aspirin, coordinate to
Ru(II) and Os(II) ions in half-sandwich complexes, providing
antitumor-active compounds.36–39 Based on these results, the
aim of our work presented here was to combine two well-known
drugs (NSAIDs) with Ru(II)–arene precursors in order to obtain
new half-sandwich Ru(II)–arene complexes with improved
cytotoxic activities. This may be a method to alter the purpose
of these drugs and to obtain potentially good cytotoxic agents.
We synthesized four new complexes and completely characterized
them. Furthermore, we investigated their cytotoxic activities by
MTT assay. In order to explain the cytotoxicity results, we have
analyzed the cell cycle, using flow-cytometric analysis and the
annexin V-FITC apoptotic assay, for quantitative analysis of
apoptotic and necrotic death of selected cells. We have also
measured the production of intracellular reactive oxygen species
(ROS) and tested the ability of the compounds to scavenge
1,1-diphenyl-picrylhydrazyl (DPPH), hydroxyl radicals (OH)
and 2,20-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
radicals and to inhibit soybean lipoxygenase (LOX) activity.
Additionally, we examined the in vitro affinity of the complexes
for bovine serum albumin (BSA) and human serum albumin
(HSA) by fluorescence emission spectroscopy as well as the
in vitro interaction of the complexes with calf-thymus (CT) DNA
by UV-vis spectroscopy, viscosity measurements and fluores-
cence emission spectroscopy.
Experimental section
Materials and measurements
RuCl33H2O was purchased from Johnson Matthey (London,
UK). Indomethacin and mefenamic acid were purchased from
TCI (Tokyo, Japan). Trisodium citrate, NaCl, CT DNA, BSA, HSA,
EB, DPPH, ABTS, sodium linoleate, butylated hydroxytoluene
(BHT), 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid
(trolox), nordihydroguaiaretic acid (NDGA) and caffeic acid were
purchased from Sigma-Aldrich. [Ru(Z6-p-cymene)Cl2]2 was pre-
pared according to a published procedure.40 [Ru(Z6-toluene)Cl2]2
was prepared according to a published procedure.41 Solvents
were obtained and used without further purification. Infrared
spectra were recorded on a Nicolet 6700 FTIR spectrometer using
the ATR technique. NMR spectra were recorded on a Bruker
Avance III 500 MHz spectrometer. Chemical shifts for 1H and
13C NMR spectra were referenced to residual 1H and 13C present
in CDCl3 or DMSO-d6. ESI mass spectra of the ruthenium
complexes were recorded on a 6210 Time-of-Flight LC-MS
instrument (G1969A, Agilent Technologies) in both positive and
negative ion modes using CH3CN/H2O or CH3CN as solvents.
UV-vis spectra were recorded in solution at concentrations in the
range of 105–103 M on a Hitachi U-2001 dual beam spectro-
photometer. Fluorescence spectra were recorded in solution on a
Hitachi F-7000 fluorescence spectrophotometer. Viscosity experi-
ments were carried out using an ALPHA L Fungilab rotational
viscometer equipped with an 18 mL LCP spindle.
DNA stock solution was prepared by dilution of CT DNA with
buffer (containing 150 mM NaCl and 15 mM trisodium citrate
at pH 7.0) followed by vigorous stirring at 4 1C for three days;
the solutions were maintained at 4 1C for no longer than two
weeks. The stock solution of CT DNA gave a ratio of UV
absorbance at 260 and 280 nm (A260/A280) in the range of 1.85
to 1.90, indicating that the DNA was sufficiently free of protein
contamination.42 The concentration of CT DNA was deter-
mined by the UV absorbance at 260 nm after 1 : 20 dilution
using e = 6600 M1 cm1.43
Synthesis of the complexes
Synthesis of K[Ru(g6-p-cymene)(indo)Cl2], 1. A solution of
Hindo (0.0584 g, 0.163 mmol) in ethanol (5 mL) was neutralized
with potassium hydroxide (9.13 mg, 0.163 mmol) and stirred
for 1 h at room temperature. After that, a suspension of
[Ru(Z6-p-cymene)Cl2]2 (0.05 g, 0.08 mmol) in ethanol (5 mL)
was added to the ligand solution, and the reaction mixture was
precipitated. The precipitate was filtered and dried in vacuo.
Yield: 62 mg, 54%. Anal. calc. for C29H29Cl3NO4RuK: C, 49.60;
H, 4.13; N, 1.99. Found: C, 49.73; H, 4.21; N, 2.09. d (ppm)
H (500 MHz; CDCl3): 1.31 (CH(CH3)2, 6H), 2.19 (CH3 cymene,
C11, C6 7H), 2.28 (CH(CH3)2, 1H), 3.43 (C9, 2H), 3.85 (C19, 3H),
5.34 (C2, C6, cym, 2H), 5.57 (C3, C5, cym, 2H), 6.64 (C3, 1H),
6.87 (C1, 1H), 6.97 (C4, 1H), 7.46 (C15, C17, 2H), 7.63 (C14, C18,
2H). d (ppm) C (125 MHz; DMSO-d6): 13.49 (C11), 19.03
(CH(CH3)2), 22.82 (CH(CH3)2), 31.61 (C6, CH(CH3)2), 56.08
(C19), 94.49 (C3, C5 cym), 100.21 (C2, C6 cym), 101.62
(C1 cym, C4 cym), 112.09 (C1), 112.26 (C3), 114.83 (C4, C7),
Fig. 1 Structure formulas of the NSAIDs Hindo and Hmef.
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129.11 (C5), 131.28 (C15, C17), 134.30 (C13), 135.62 (C14, C18),
139.24 (C8, C16), 156.01 (C2), 168.60 (C10, C12). IR (ATR),
nmax/cm
1: 2963 (C–H), 1686 (CQO), 1453 (C–Car), 1261
(C–Ov), 1226 (C–Hd), 841 (C–Hg). LC-ESI/MS, m/z (M, %):
592.08 ([M  K  2Cl]+, 18), 633.11 ([M  K  Cl + H]+, 45).
Synthesis of (NH4)[Ru(g
6-p-cymene)(mef)Cl2], 2. A suspen-
sion of Hmef (0.04 g, 0.163 mmol) in methanol (5 mL) was
added to a suspension of [Ru(Z6-p-cymene)Cl2]2 in methanol
(5 mL). The reaction mixture was stirred at room temperature
for 1 h. The orange suspension was than concentrated in vacuo
to 5 mL, and solid NH4PF6 (0.03 g) was added. The mixture was
stirred at room temperature for 2 h. The resulting orange
precipitate was filtered and dried in vacuo. Yield: 51 mg, 55%.
Anal. calc. for C25H32Cl2N2O2Ru: C, 53.18; H, 5.67; N, 4.96.
Found: C, 53.60; H, 5.69; N, 4.53. d (ppm) H (500 MHz; DMSO-
d6): 1.20 (CH(CH3)2, 6H), 2.10 (C14, 3H; CH3 cym, 3H), 2.29
(C15, 3H), 2.86 (CH(CH3)2, 1H), 5.78 (C2, C6, cymene 2H), 5.90–
6.10 (C3, C5 cymene 2H), 6.69 (C11, C13) 7.03–7.13 (C12, C4,
C5), 7.31 (C3, 1H), 7.88 (C6, 1H), 9.44 (NH). d (ppm) C (125
MHz; DMSO-d6): 13.43 (C15), 18.12 (CH3), 19.76 (C14), 21.41
(CH(CH3)2), 29.61 (CH(CH3)2), 85.37 (C3 cym), 86.41 (C5 cym),
89.31 (C2 cym), 95.33 (C6 cym) 100.03 (C4 cym), 106.36
(C1 cym), 111.20 (C6), 112.92 (C2), 116.15 (C4), 122.32 (C11),
126.02 (C12), 126.41 (C13), 131.10 (C3), 131.57 (C9), 134.19 (C5),
137.87 (C10), 138.28 (C8), 148.56 (C7), 169.97 (C1). IR (ATR),
nmax/cm
1: 3309 (N–Hv), 2975–2871 (C–Hv), 1649 (CQOv), 1497
(C–Car), 1257 (C–Ov), 1159 and 1054 (C–Hd), 835 (C–Hg). LC-ESI/
MS, m/z (M, %): 432.24 ([M  NH4  2Cl  CH(CH3)2]+, 8),
476.12 ([M  NH4  2Cl]+, 10), 576.94 ([M + CH3OH]+, 100).
Synthesis of K[Ru(g6-p-toluene)(indo)Cl2], 3. The synthesis
of complex 3 is the same as for complex 1 with the use of
[Ru(Z6-toluene)Cl2]2 instead of [Ru(Z
6-p-cymene)Cl2]2. The
resulting orange precipitate was filtered and dried in vacuo.
Yield: 70 mg, 65%. Anal. calc. for C26H22Cl3NO4RuKCH3OH: C,
46.90; H, 3.76; N, 2.03. Found: C, 46.60; H, 3.61; N, 2.09. d
(ppm) H (500 MHz; DMSO-d6): 2.07 (C11, 3H), 2.14 (CH3 tol,
3H), 3.52 (C9, 1H), 3.72 (C19, 1H), 5.71 (C2, C4, C6, tol 3H), 5.98
(C3, C5, tol 2H), 6.71 (C3, 1H), 6.96 (C1, 1H), 7.23 (C4, C15, 2H),
7.65 (C14, C17, C18, 3H). d (ppm) C (125 MHz; DMSO-d6): 13.94
(C11), 19.24 (C7 tol), 33.19 (C9), 55.91 (C19), 82.60 (C4 tol),
85.03 (C3, C5 tol), 89.77 (C2, C6 tol), 102.19 (C1), 105.87 (C1 tol),
111.48 (C3), 113.76 (C4), 114.91 (C7), 126.10 (C5) 128.59 (C15),
129.39–131.46 (C14, C17, C18), 134.22 (C6, C13), 137.95
(C8, C16), 155.86 (C2), 168.06 (C12), 182.97 (C10). IR (ATR),
nmax/cm
1: 2972 (C–Hv), 1648 (CQOv), 1447 (C–Car), 1257
(C–Ov), 1158 (C–Hd), 835.50 (C–Hg). LC-ESI/MS, m/z (M, %):
negative mode 621.97 ([M  K+], 25), positive mode 623.97
([M  K+ + 2H]+, 15), 550.04 ([M  K+  2Cl + H]+, 10).
Synthesis of (NH4)[Ru(g
6-p-toluene)(mef)Cl2], 4. The synthesis
of complex 4 is the same as for complex 2 with the use of
[Ru(Z6-toluene)Cl2]2 instead of [Ru(Z
6-p-cymene)Cl2]2. The
resulting yellow precipitate was filtered and dried in vacuo.
Yield: 32.2 mg, 54.12%. Anal. calc. for C22H25Cl2N2O2Ru2CH3OH:
C, 49.22; H, 5.45; N, 4.78. Found: C, 49.68; H, 5.13; N, 4.38. d (ppm)
H (500 MHz; DMSO-d6): 2.10 (C14, 3H), 2.30 (CH3 tol, 3H),
5.71 (C2,4,6 tol, 3H), 5.97 (C3,5 tol, 2H), 6.67–6.69 (C11, C13, 2H),
7.11–7.19 (C12, C4, C5, C3 4H), 7.90 (C6, 1H), 9.46 (NH). d (ppm)
C (125 MHz; DMSO-d6): 13.87 (CH3 tol), 20.43 (C15), 21.23 (C14),
82.36 (C4 tol), 85.15 (C3, C5 tol), 89.94 (C2, C6 tol), 111.46 (C1 tol,
C6), 111.76 (C2), 113.55 (C4), 116.69 (11), 122.22 (C12), 125.32 (C13),
128.44 (C3), 131.14 (C9), 131.96 (C5), 134.55 (C10), 138.57 (C8),
148.81 (C7), 170.62 (C1). IR (ATR), nmax/cm1: 3309 (N–Hv), 3085
(C–Hv), 1649 (CQOv), 1449 (C–Car), 1253 (C–Ov), 1157 (C–Hd), 829
(C–Hg). LC-ESI/MS, m/z (M, %): 541.98 ([M + NH4]
+, 25), 432.13
([M  NH4  2Cl]+, 10).
Cell lines and culture conditions
K562 (human myelogenous leukemia), A549 (human lung
adenocarcinoma) and MRC-5 (non-tumor human lung fibroblast)
cells were maintained in Roswell Park Memorial Institute (RPMI)
1640 nutrient medium (Sigma-Aldrich Co). MDA-MB-231 (human
breast adenocarcinoma) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Sigma-Aldrich Co). RPMI
1640 nutrient medium was prepared in sterile ionized water
and supplemented with penicillin (192 U mL1), streptomycin
(200 mg mL1), 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic
acid (HEPES) (25 mM), L-glutamine (3 mM) and 10% heat-
inactivated fetal calf serum (FCS) (pH 7.2). To maintain the
MDA-MB-231 cell line, DMEM was additionally supplemented
with D-glucose (4.5 g L1). Cells were maintained as monolayer
cultures in tissue culture flasks (Thermo Scientific NuncTM) in
an incubator at 37 1C in a humidified air atmosphere composed
of 5% CO2.
MTT assay
The cytotoxicities of the investigated ruthenium(II) compounds
and CDDP (cis-diamminedichloridoplatinum(II), cisplatin)44 as a
reference compound were determined using the 3-(4,5-dimethyl-
thiazol-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich
Co) assay.45 Cells were seeded into 96-well culture plates (Thermo
Scientific NuncTM). Due to the different morphological and
physiological features of the different cell lines, cells were seeded
at cell densities of 6000 c/w (K562), 7000 c/w (A549 and MDA-MB-
231) and 8000 c/w (MRC-5) in 100 mL of culture medium. 24 h
after seeding, the cells were exposed to serial dilutions of the
tested compounds. Stock solutions of the investigated com-
pounds were prepared by dissolving each compound in dimethyl
sulfoxide (DMSO) at a concentration of 10 mM (the final concen-
tration of DMSO did not exceed 1% per well) immediately prior to
use,46 followed by dilution with nutrient medium to the desired
final concentrations (in the range of 0 to 300 mM). The stabilities
of the complexes in DMSO/phosphate buffer (pH 7.4) = 1/100
(volume ratio) were monitored by UV-vis spectroscopy, and their
stabilities under these conditions were proved.
Each concentration was tested in triplicate. After 72 h of
continuous drug incubation, 20 mL of MTT solution (5 mg mL1
in phosphate buffer solution (PBS), pH 7.2), was added to each
well. Samples were incubated for the next 4 h at 37 1C with
5% CO2 in a humidified air atmosphere. The purple formazan
products were dissolved in 100 mL of 10% sodium dodecyl
sulfate (SDS). Absorbances were recorded after 24 h on a micro-
plate reader (Thermo Labsystems Multiskan EX 200-240V) at a
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wavelength of 570 nm. The IC50 values (concentration of investi-
gated agent that decreases the number of viable cells by 50% in a
treated cell population compared to a non-treated control) were
estimated from the dose–response curves.
Cell cycle analysis
Flow-cytometric analysis of the cell cycle phase distribution was
performed in MDA-MB-231 cells after staining the fixed cells
with propidium iodide (PI).47 We examined the effects of
complexes 1 and 3, which displayed the most prominent
cytotoxicity, in comparison to CDDP as a reference compound;
MDA-MB-231 cells were seeded at a density of 3  105 cells per
well into 6-well plates (Thermo Scientific Nunct) in the nutri-
tion medium. After 24 h of growth, the cells were continually
exposed to complexes 1 and 3 or CDDP at concentrations
corresponding to 0.5  IC50 and IC50: complex 1 (11 mM and
22 mM), complex 3 (13 mM and 26 mM) and CDDP (8 mM and
16 mM). After 24 h of treatment, cells were collected by trypsi-
nization, washed twice with ice-cold PBS, and fixed for 30 min
in 70% ethanol. Fixed cells were washed again with PBS
and incubated with RNaseA (1 mg mL1) for 30 min at 37 1C.
Immediately before flow-cytometric analysis, cells were stained
with PI at a concentration of 400 mg mL1. The cell cycle phase
distribution was analyzed using a fluorescence activated cell
sorting (FACS) Calibur Becton Dickinson flow cytometer and
Cell Quest computer software (Becton Dickinson, Heidelberg,
Germany).
Annexin V-FITC apoptotic assay
Quantitative analysis of apoptotic and necrotic death of MDA-
MB-231 cells induced by complexes 1 and 3 and CDDP as a
reference compound were performed using an Annexin V-FITC
apoptosis detection kit according to the manufacturer’s instruc-
tions (BD Biosciences, Pharmingen San Diego, CA, USA). Briefly,
1  106 cells per mL were treated with complexes 1 and 3 and
CDDP at concentrations corresponding to 0.5  IC50 and IC50 for
24 h. After treatment, the cells were collected, washed twice with
ice-cold PBS and then resuspended in 200 mL 1 Binding Buffer
(10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).
100 mL of cell suspension (containing approximately 1  105 cells)
was transferred to a 5 mL culture tube and mixed with 5 mL of
both Annexin V-FITC and PI. The cells were gently vortexed and
incubated for 15 min at 25 1C in the dark. After the incubation
period, 400 mL of 1 Binding Buffer was added to each sample,
which was then analyzed using a FACS Calibur Becton Dickinson
flow cytometer and Cell Quest computer software (Becton
Dickinson, Heidelberg, Germany).
Measurement of intracellular reactive oxygen species
Generation of reactive oxygen species (ROS) in MDA-MB-231
cells after treatment with complexes 1 and 3 and CDDP was
measured using a ROS-sensitive fluorophore, 20,70-dichloro-
dihydrofluorescein diacetate (DCFH-DA, Sigma-Aldrich Co).48
Briefly, 3  105 MDA-MB-231 cells per well were seeded into
6-well plates (Thermo Scientific Nunct) in nutrition medium.
After 24 h of growth, the cells were treated with complexes 1
and 3 and CDDP at concentrations corresponding to their
IC50 values for 4 h. After treatment, the cells were harvested,
washed twice with ice-cold PBS, re-suspended in 1 mL of 50 mM
DCFH-DA and incubated for 30 min at 37 1C in the dark. After
incubation with the dye, the cells were washed with PBS,
re-suspended in 300 mL of PBS and immediately analyzed using
the FL1 channel of the FACS Calibur Becton Dickinson flow
cytometer and using Cell Quest computer software (Becton
Dickinson, Heidelberg, Germany). The excitation wavelength
used in the measurements was 485 nm, with peak emission
measured at 530 nm. Subsequently, the geomean of the DCFH-
DA-dependent fluorescence was determined.
Antioxidant activity
The antioxidant activities of complexes 1–4 were evaluated via
their ability to scavenge free radicals such as DPPH, hydroxyl
and ABTS. Furthermore, their ability to inhibit the activity of
soybean lipoxygenase was also studied. Each experiment
was performed in triplicate, and the standard deviation of
absorbance was less than 10% of the mean.
Determination of the reducing activity of the stable radical
DPPH. To an ethanolic solution of DPPH (0.1 mM), an equal
volume of an ethanolic solution of the compound was added.
The concentration of the solution of the compound was
0.1 mM. Ethanol was also used as a control solution. The
absorbance at 517 nm was recorded at room temperature after
20 and 60 min in order to examine the time-dependence of
the DPPH radical scavenging activity.49a,b The DPPH radical
scavenging activity of the compounds was expressed as the
percentage reduction of the absorbance value of the initial
DPPH solution (RA%). NDGA and BHT were used as reference
compounds.
Competition of the tested compounds with DMSO for hydroxyl
radicals. The hydroxyl radicals generated by the Fe3+/ascorbic acid
system were detected by the determination of formaldehyde
produced from the oxidation of DMSO, according to Nash.50
The reaction mixture contained EDTA (0.1 mM), Fe3+ (167 mM),
DMSO (33 mM) in phosphate buffer (50 mM, pH 7.4), the tested
compound (concentration 0.1 mM) and ascorbic acid (10 mM).
After 30 min of incubation (37 1C) the reaction was stopped with
CCl3COOH (17% w/v) and the absorbance at l = 412 nm was
measured. Trolox was used as an appropriate standard. The
competition of the compounds with DMSO for OH generated
by the Fe3+/ascorbic acid system, expressed as the percent inhibi-
tion of formaldehyde production, was used for evaluation of their
hydroxyl radical scavenging activities (OH%).
Assay of radical cation scavenging activity. ABTS radical
cation (ABTS+) was produced by reacting an aqueous stock
solution (2 mM) of ABTS with 0.17 mM potassium persulfate
and allowing the mixture to stand in the dark at room tem-
perature for 12 to 16 h before use. Because ABTS and potassium
persulfate react stoichiometrically at a ratio of 1 : 0.5, this will
result in incomplete oxidation of the ABTS. Although the
oxidation of the ABTS commenced immediately, the absor-
bance became maximal and stable after 6 h. The radical was
stable in this form for more than 2 days when stored in the dark
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at room temperature. The ABTS+ solution was diluted with
ethanol to an absorbance of 0.70 at 734 nm. After addition of
10 mL of diluted compound or standard (0.1 mM) in DMSO,
the absorbance reading was taken exactly 1 min after the initial
mixing.49a The radical scavenging activity of the complexes was
expressed as the percentage inhibition of the absorbance of
the initial ABTS solution (ABTS%). Trolox was used as an
appropriate standard.
Soybean lipoxygenase inhibition study in vitro. The in vitro
soybean lipoxygenase inhibition was evaluated as reported
previously.49a The tested compounds were dissolved in ethanol
and were incubated at room temperature with sodium linoleate
(0.1 mM) and 0.2 mL of enzyme solution (1/9  104 w/v in
saline). The conversion of sodium linoleate to 13-hydroperoxylinoleic
acid at 234 nm was recorded and compared with the appropriate
standard inhibitor caffeic acid.
Albumin binding studies
The albumin binding studies were performed by tryptophan
fluorescence quenching experiments using bovine serum albumin
(BSA, 3 mM) or human serum albumin (HSA, 3 mM) in buffer
(containing 15 mM trisodium citrate and 150 mM NaCl at
pH 7.0). The quenching of the emission intensity of tryptophan
residues of BSA at 343 nm or HSA at 351 nm was monitored
using complexes 1–4 as quenchers with increasing concentration.51
The fluorescence emission spectra were recorded in the range
of 300 to 500 nm with an excitation wavelength of 295 nm. The
fluorescence emission spectra of the free compounds were also
recorded under the same experimental conditions, i.e. excitation
at 295 nm; the complexes bearing indomethacin ligands (i.e.
1 and 3) exhibited a low emission band at B365 nm,22 while
those bearing mefenamato ligands (i.e. 2 and 4) did not exhibit
any appreciable emission bands.30 Therefore, in order to perform
quantitative studies of the interaction with serum albumins, the
fluorescence emission spectra of the indomethacin complexes 1
and 3 were corrected by subtracting the spectra of the compounds.
The influence of the inner-filter effect52 on the measurements was
evaluated by eqn (S1) (ESI†). The Stern–Volmer and Scatchard
equations (eqn (S2)–(S4), ESI†) and graphs53a–c were used in
order to calculate the Stern–Volmer constant KSV (in M
1), the
SA-quenching constant (kq, in M
1 s1), the SA-binding constant K
(in M1) and the number of binding sites per albumin (n).
DNA binding studies
The interaction of complexes 1–4 with CT DNA was studied by
UV-vis spectroscopy in order to investigate the possible binding
modes to CT DNA and to calculate the DNA-binding constants
(Kb). The UV-vis spectra of CT DNA (0.15 to 0.18 mM) were
recorded in the presence of each compound with diverse
[complex]/[DNA] mixing ratios (= r). The Kb constants (in M
1)
were determined by the Wolfe–Shimmer equation (eqn (S5),
ESI†)54a,b and the plots of [DNA]/(eA  ef) versus [DNA] using the
UV-vis spectra of the complex (50 to 100 mM) recorded in the
presence of DNA for diverse r values.55a Control experiments
with DMSO were performed, and no changes in the spectra of
CT DNA were observed.
The viscosity of DNA ([DNA] = 0.1 mM) in buffer solution
(150 mM NaCl and 15 mM trisodium citrate at pH 7.0) was
measured in the presence of increasing amounts of complexes
1–4 (up to the value of r = 0.35). All measurements were
performed at room temperature. The obtained data are pre-
sented as (Z/Z0)
1/3 versus r, where Z is the viscosity of DNA in the
presence of the compound and Z0 is the viscosity of DNA alone
in buffer solution.
The competitive studies of complexes 1–4 with EB were
investigated by fluorescence emission spectroscopy in order
to examine if the complexes could displace EB from its CT
DNA–EB conjugate. The CT DNA–EB conjugate was prepared by
adding 20 mM EB and 26 mM CT DNA in buffer (150 mM NaCl
and 15 mM trisodium citrate at pH 7.0). The intercalating
effects of the complexes were studied by stepwise addition of
a certain amount of a solution of the compound into a solution
of the DNA–EB conjugate. The influence of the addition of each
compound to the DNA–EB complex solution was obtained
by monitoring the changes of the fluorescence emission
spectra recorded with an excitation wavelength (lex) at
540 nm. Complexes 1–4 did not show any fluorescence emission
bands at room temperature in solution or in the presence of CT
DNA or EB under the same experimental conditions (lex = 540 nm);
therefore, the observed quenching is attributed to the displace-
ment of EB from its EB–DNA conjugate. The Stern–Volmer
constants (KSV, in M
1) were calculated according to the linear
Stern–Volmer equation (eqn (S2), ESI†)53b and the plots of
I0/I versus [Q]. The quenching constants (kq, in M
1 s1) of the
complexes were calculated according to eqn (S3) (ESI†) because the
fluorescence lifetime of the EB–DNA system is t0 = 23 ns.
55b
Results and discussion
Synthesis and characterization of Ru complexes
Reaction of [Ru(Z6-arene)Cl2]2, namely [Ru(Z
6-p-cymene)Cl2]2
or [Ru(Z6-toluene)Cl2]2, with stoichiometric amounts of the
corresponding NSAID ligands, indomethacin (Hindo) and
mefenamic acid (Hmef), led to the formation of two cymene
complexes, [Ru(Z6-p-cymene)(indo)Cl2]
 1 and [Ru(Z6-p-cymene)-
(mef)Cl2]
 2, and two toluene complexes, [Ru(Z6-toluene)(indo)Cl2]

3 and [Ru(Z6-toluene)(mef)Cl2]
 4, in reasonably good yields.
The resulting complexes 1 and 3 precipitated after neutralization
with potassium hydroxide, and complexes 2 and 4 precipitated
after addition of ammonium hexafluorophosphate to the
reaction mixture (Scheme 1). Complexes 1 and 3 showed good
solubility in acetonitrile, dimethylsulfoxide, and chloroform and
lower solubility in ethanol and methanol. Complexes 2 and 4
showed excellent solubility in all these solvents.
The IR spectra of the free NSAIDs show characteristic
absorption bands for the n(O–H) vibration at about 3500 cm1.
These absorption bands did not appear in the IR spectra of the
complexes, indicating ligand coordination via carboxylate anions.
Due to this, the coordination absorption bands for carbonyl group
stretching at 1650 to 1700 cm1 in the complexes were also
slightly shifted to lower values.
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Upon complexation to the metal, the symmetries of [Ru(Z6-
p-cymene)Cl2]2 and [Ru(Z
6-toluene)Cl2]2 decreased. The cymene
and toluene ring protons as well as the protons from the ligand
moiety in the complexes exhibited slightly lower chemical
shifts in comparison to the starting complexes or the ligands
themselves. Signals for protons from the carboxylic group in
the 1H NMR spectra of all complexes did not appear due to
deprotonation and coordination.
The 13C NMR spectra of the synthesized complexes did not
suffer significant changes. Chemical shifts for carbon atoms
from the arene moiety were slightly moved to higher values.
Values for chemical shifts corresponding to carbon atoms from
the carboxylate groups were higher in the complexes compared
to the free ligands (Fig. S1–S8, ESI†).
Finally, mass spectra of the complexes were recorded both
in positive and negative ion mode. The molecular ion was
detected only in the case of complex 3, m/z values 621.9 in
negative mode and 623 in positive mode, while in other cases,
only the anionic parts of the complexes with or without Cl ions
were detected: [M  K+  2Cl + H]+ (1, 3) and [M  NH4  2Cl]+
(2, 4).
MTT assay
The cytotoxic activities of the novel ruthenium(II) complexes 1–4, as
well as the free NSAID ligands, indomethacin andmefenamic acid,
in comparison to cisplatin (CDDP) were investigated by MTT
assay. The study was performed in three human cancer cell lines
(K562, A549, MDA-MB-231) and in one human non-tumor cell line
(MRC-5). The results obtained after 72 h of continuous drug action
are presented as IC50 values (mM) (Table 1) provided from cell
survival diagrams (Fig. 2). Complexes 1–4 exhibited generally
higher cytotoxic activity compared to free NSAIDs, Hindo and
Hmef, although the IC50 values of complexes varied in the micro-
molar range from 11.9 to 275.7 mM depending on the cell line.
Complexes 1 and 3, carrying indomethacin ligands, showed the
highest cytotoxic potential. The human myelogenous leukemia
K562 cell line proved to be the most sensitive to the actions of 1
and 3 (IC50 values: 11.9 mM and 13.2 mM, respectively). These
values were comparable to cisplatin (IC50 = 10.3 mM), and were
significantly lower than the IC50 values obtained for complexes 2
(IC50 = 96.4 mM), and 4 (IC50 = 133 mM). Interestingly, MDA-MB-231
cells exhibited much greater sensitivity toward 1 and 3 than CDDP-
resistant lung carcinoma A549 cells and non-tumor MRC-5 cells.
The results for MRC-5 indicated that this cell line was at least
4 times less sensitive to 1–4 than to CDDP. The NSAIDs exhibited
poor activity, up to 300 mM, while Hmef could be considered
inactive in MRC-5. A structure–activity comparison revealed that
Scheme 1 Reaction scheme for the synthesis of complexes 1–4.
Table 1 IC50 values (mM) obtained after 72 h of continuous drug action
a
Compound K562 A549 MDA-MB-231 MRC-5
1 11.9  4.4 45.5  2.7 22  3.6 39.6  3.7
2 96.4  2 145.1  6.4 153  1.2 222.6  23.9
3 13.2  6.2 31.7  1.15 26  1.7 42  1.3
4 133  7 142.4  9.3 121.4  1.8 275.7  14.5
Hindo 155.9  11.4 161.5  13.9 244.7  17.8 230.5  17.8
Hmef 143.9  4.1 217.3  46.7 237.9  18.8 4300
CDDP 10.3  1.2 13.6  1.8 15.9  2.1 9.3  0.9
a IC50 values (mM) are presented as the mean  SEM of three independent
experiments. 4300 denotes that IC50 was not obtained in the range of
concentrations tested up to 300 mM.
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the NSAID Hindo enhanced the cytotoxicity of the resulting
ruthenium(II)–arene complexes 1 and 3 despite having poor activity
itself. On the other hand, p-bonded arene ligands such as
p-cymene (in complexes 1 and 2) or toluene (in complexes 3 and 4)
appeared to have no significant impact on the in vitro cytotoxic
potential of the complexes. Triple-negative breast cancer cells such
asMDA-MB-231 are characterized by highmetastatic potential and
lack of specific molecular targets for effective therapy; thus,
the results of the present study indicated that ruthenium-based
‘‘combi-molecules’’ may represent a promising alternative for
treatment of this type of cancer (Table S1, ESI†).
Cell cycle analysis
The capability of complexes 1, 3 and CDDP to induce cell
cycle alterations was examined by flow cytometry after 24 h
of continual treatment and staining with PI. Triple-negative
breast carcinoma MDA-MB-231 cells were chosen to further
investigate the mechanism of action of complexes 1 and 3. The
results are presented in Fig. 3 as diagrams of cell distribution
over the cell cycle phases. At low 0.5  IC50 concentrations,
both 1 and 3 affected cell cycle progression in a manner
different from that of cisplatin, causing slight accumulation
of cells in G2-M phase and a decrease in G1 phase. Cell cycle
changes progressed at higher concentrations of the tested
complexes 1 and 3 (IC50) and were characterized by rapid
accumulation of cells in sub-G1, up to 48.5% (1) and 47.09%
(3) compared to the control (0.03%). There was a decrease in
the cell population in the G2-M and G1 phases and arrest in the
S phase of the cell cycle, up to 18.66% (1) and 20.95% (3) versus
the control (14.24%). Obviously, cells that could not progress
through S phase following action of 1 and 3 (at IC50) entered
cell death and accumulated in sub-G1 phase. Formation of the
Sub-G1 or hypodiploid peak is considered to be a hallmark of
fragmented DNA.56,57 Further UV-vis spectroscopic studies also
Fig. 2 Cell survival curves after 72 h of treatment of K562, A549, MDA-MB-231 and MRC-5 cell lines with (A) complex 1 and (B) complex 3.
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demonstrated the potential of complexes 1 and 3 to bind to
DNA (Table 4) and support these findings. The potential of
different metal ions conjugated to NSAIDs to damage DNA and
alter the cell cycle was previously demonstrated.58–60 Recent
investigation by Kasparkova and colleagues58 of new Pt(II)
conjugates carrying the NSAID diclofenac demonstrated
their potential to act as a so-called ‘‘combi-molecule’’ which
combines the DNA-binding properties of the metal center and
antitumor properties of NSAID ligands for cytotoxic activity.
The results of the present study strongly suggested the ability of
complexes 1 and 3 to cause damage to DNA and arrest DNA
replication, either through direct DNA-binding or by an indirect
mechanism.
Annexin V-FITC apoptotic assay
Because MDA-MB-231 cells exhibited particular sensitivity to
the cytotoxic action of complexes 1 and 3 (IC50 value), showing
an intense Sub-G1 peak, we further investigated whether the
apoptotic or necrotic changes underlie the mechanism of cell
death. The potential of the investigated compounds or CDDP to
induce apoptosis/necrosis in MDA-MB-231 cells was assessed
by flow cytometry following Annexin-V-FITC/PI dual staining
after 24 h of continual drug treatment. The results (Fig. 4A)
show the percentage of early apoptotic cells, labeled FITC(+)/
PI(), late apoptotic cells, FITC(+)/PI(+), and necrotic cells,
FITC()/PI(+).
The obtained experimental data indicated that both complexes
1 and 3 as well as CDDP initiated apoptosis in a concentration-
dependent manner. At 0.5  IC50 concentrations, 1 and 3 caused
7.96% and 6.73% of FITC(+)/PI() staining, respectively. These
values were comparable to those of cisplatin, where 6.75% of cells
were apoptotic, versus 4.41% in the control. As the dose of the
compounds increased, the cells shifted from the healthy state,
FITC()/PI(), to either early apoptotic, FITC(+)/PI(), or necrotic,
FITC(+)/PI(+). Particularly significant dose-dependent effects on
the cell redistribution between quadrants were observed after
treatment with complexes 1 and 3. At IC50 concentrations of 1
and 3, percentages of early apoptotic cells increased up to 20%,
which is 3 times more than for the cells treated with CDDP.
Simultaneously, FITC(+)/PI(+) staining, characteristic for necrosis,
increased up to 20%. Results of the Annexin-V-FITC/PI apoptosis
assay are in accordance with the cell cycle study, which confirmed
that under the same treatment conditions (IC50, 24 h), more than
40% of cells underwent DNA-fragmentation and accumulated in
Sub-G1 phase as either apoptotic or necrotic cells.
Measurement of intracellular reactive oxygen species
To investigate whether induced cytotoxic and apoptotic effects
of synthesized ruthenium(II)–arene complexes 1 and 3 are
related to ROS production, we measured the intracellular ROS
levels in MDA-MB-231 cells after 4 h of treatment with the
tested complexes 1 and 3 or CDDP at concentrations corres-
ponding to their IC50 values. As illustrated in Fig. 5A, the ROS
level did not change significantly after 4 h exposure to CDDP.
However, after 4 h of treatment with complexes 1 and 3, slight
changes in the shapes of the fluorescent signal curves can
be noted. Fluorescence of DCFH-DA in the treated cells is red-
shifted toward a higher intensity compared to the control cells
(Fig. 5B). This shift implies modest production of intracellular
reactive oxygen species for 3.9% of cells treated with 1 and
5.42% of cells treated with 3; these values are higher than those
of the control cells (2%) and cisplatin (1.88%) (Fig. 5C).
However, a study of the scavenging abilities of the tested
complexes for DPPH, superoxide radical and hydroxyl radical
showed that complex 1 exhibited the highest ROS scavenging
properties. Certainly, additional studies are needed in order to
precisely address the features of the tested complexes that
dominate the mechanisms of their cytotoxic action. The notice-
able changes in ROS levels under treatment at an early time
point (4 h) suggest that these complexes exhibit a strong,
Fig. 3 Diagrams of cell cycle phase distributions of treated MDA-MB-231 cells after 24 h of treatment with complexes 1, 3 and CDDP at concentrations
corresponding to 0.5  IC50 and IC50.
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Fig. 4 (A) Bar graph of apoptosis and necrosis, quantified by FACS, after Annexin V-FITC and PI labelling. (B) Dot plot diagrams following 24 h treatment
of MDA-MB-231 cells with complexes 1 and 3 or CDDP at concentrations corresponding to 0.5  IC50 and IC50. Representative dot plots of
three independent experiments are given, presenting intact cells in the lower-left quadrant, FITC()/PI(); early apoptotic cells in the lower-right
quadrant, FITC(+)/PI(); late apoptotic or necrotic cells in the upper-right quadrant, FITC(+)/PI(+); and necrotic cells in the upper-left quadrant,
FITC()/PI(+).
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Fig. 5 Effects of complexes 1, 3 and CDDP on intracellular ROS levels. MDA-MB-231 cells were treated for 4 h with the tested compounds at
concentrations corresponding to their IC50 values and subjected to flow cytometry-based oxidative stress analysis for measurement of the ROS levels.
Intracellular oxidative stress is indicated on the horizontal axis and corresponds to the fluorescence intensity of DCFH-DA. The vertical axis shows the cell
numbers. (A) Representative histograms of one of three independent experiments, presenting the percentage of increase of ROS accumulation in treated
cells relative to control cells; (B) enhancement of intracellular ROS accumulation, observed via the shift of the signal curve obtained for the treated cells
(presented as a line) to the right compared with that of the control cells (presented as a filled curve); (C) bar graph presenting the mean fluorescence
intensities of DCFH-DA of three independent experiments.
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multiple-layer cytotoxic effect, possibly triggered by ROS release
and afterwards by induction of cell death. Previous literature
data on the in vitro antitumor effects of NSAID agents, such
as acetylsalicylic acid (aspirin), reported their potential to
synergistically enhance the cytotoxicity of cisplatin or other
chemotherapeutic anticancer agents by different mechanisms,
including cell cycle alteration or induction of apoptosis through
oxidative stress and mitochondrial dysfunction.59,61–63 The
results of the present study signify that NSAIDs conjugated
with ruthenium–arenes represent a promising class of agents
with unique in vitro anti-tumor features resulting from the
combined properties of both ruthenium–arenes and NSAIDs.
Antioxidant activities of the complexes
Compounds that can scavenge free radicals or inhibit their
production have potential applications in the treatment of
inflammation49a,b because free radicals are species involved
in the inflammatory process. Within this context, the in vitro
antioxidant activities of complexes 1–4, i.e. the in vitro scavenging
activities of complexes 1–4 towards DPPH, ABTS and hydroxyl
radicals, and their ability to inhibit the activity of soybean
lipoxygenase have been studied and have been compared to
the well-known antioxidant agents NDGA, BHT, trolox and
caffeic acid, which were used as standard reference compounds
(Table 2).
The ability of complexes 1–4 to scavenge DPPH radicals
(which is usually closely related to antiageing, anticancer and
anti-inflammatory activity)49a,b was time-independent because
no significant differences were observed after treatment for
20 min and 60 min. On average, complexes 1–4 were better
DPPH-scavengers than the corresponding free NSAIDs Hindo
and Hmef but less active than the reference compounds BHT
and NDGA. Complexes 1 and 3, bearing indomethacin ligands,
were more potent than their analogues 2 and 4, respectively.
Complex 1 was found to be the best DPPH-scavenger among the
present complexes.
The scavenging of hydroxyl radicals (OH) usually indicates
that the compounds may offer relief from the presence of
reactive oxygen species.49a,b The scavenging ability of the
complexes towards hydroxyl radicals is significantly high; all
complexes 1–4 were more active than the corresponding free
NSAIDs, Hindo and Hmef, and more active than the reference
compound trolox. Complexes 1 and 2, which contain the arene
p-cymene, are the most active hydroxyl-scavengers among the
present compounds.
The scavenging of cationic ABTS radicals (ABTS+) is often
used as a marker of total antioxidant activity.49a Regarding the
ABTS scavenging ability of complexes 1–4, the complexes are
more active than the corresponding free NSAIDs, Hindo and
Hmef, but less active than the reference compound trolox.
Complexes 1 and 3 bearing indomethacin as a ligand are better
ABTS-scavengers than their mefenamato analogues 2 and 4,
respectively. Complex 1 is the most active ABTS-scavenger
among complexes 1–4.
Compounds that can inhibit the activity of LOX may be
considered as potential antioxidants or free radical scavengers
because lipoxygenation is a procedure which usually occurs via
a carbon-centered radical.64 In comparison with the reference
compound caffeic acid, complexes 1–4 are very potent LOX
inhibitors, with the indomethacin complexes 1 and 3 being the
most active compounds.
In general, complexes 1–4 are better radical scavengers than
the corresponding free NSAIDs Hindo and Hmef, suggesting that
their coordination to Ru(II) results in enhanced scavenging activity.
In comparison with reportedmetal–NSAID analogues,17,22,29–33,65–69
the present complexes 1–4 are significantly active DPPH-, ABTS-
and hydroxyl-scavengers and LOX-inhibitors. Although the number
of the present compounds is rather low to clarify the structural
factors that lead to enhanced antioxidant activity, we suggest that
the complexes bearing indomethacin and/or p-cymene are themost
potent compounds; as a result, complex 1was found to be themost
active compound. Furthermore, the complexes are more active
scavengers of hydroxyl and ABTS radicals than of DPPH radicals;
this scavenging selectivity for hydroxyl and ABTS radicals has been
previously reported in the literature,70–72 especially for metal–
NSAID complexes.17,22,29–33,65–69
Interaction with biomolecules
Interaction of the complexes with albumins. The most
important role of the serum albumins (SAs) is the transporta-
tion of ions and drugs towards their biological targets, i.e. cells
and tissues.50 Within this context, the study of the interaction
of biologically potent compounds (such as the reported
complexes 1–4) with SAs can be considered as an approach
for the exploration of potential biological activity and applica-
tions. As a result of this interaction, the biological properties of
Table 2 %DPPH scavenging ability (RA%), % superoxide radical scavenging activity (ABTS%), competition with DMSO for hydroxyl radical (OH%), and
in vitro inhibition of soybean lipoxygenase (LOX, IC50 in mM) for Hindo and Hmef and their complexes 1–4
Compound RA%, 20 min RA%, 60 min OH% ABTS% LOX
1 34.23  0.35 33.26  0.66 96.89  0.33 88.11  0.92 29.76  0.12
2 13.67  0.35 15.16  0.42 96.58  0.11 78.21  0.27 34.56  0.17
3 26.58  0.41 25.42  0.17 93.41  0.16 82.54  0.23 27.34  0.55
4 8.82  0.47 9.24  0.48 93.56  0.38 72.61  0.86 40.54  0.73
Hindo 20.32  0.73 24.65  0.47 91.34  0.74 79.64  0.30 34.46  0.59
Hmef 5.72  0.08 11.74  0.20 92.51  0.44 66.32  0.38 48.52  0.88
NDGA 81.02  0.18 82.60  0.17 Not tested Not tested Not tested
BHT 31.30  0.10 60.00  0.38 Not tested Not tested Not tested
Trolox Not tested Not tested 82.80  0.13 91.8  0.17 Not tested
Caffeic acid Not tested Not tested Not tested Not tested 600  0.3
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the compounds may alter when bound to albumins, or novel
alternative pathways or mechanisms of activity and transporta-
tion may be revealed.73 Therefore, the interaction of complexes
1–4 with HSA and its homologue BSA were studied by fluores-
cence emission spectroscopy. The solutions of HSA and BSA
exhibit intense fluorescence emission bands at lem,max =
352 nm and 343 nm, respectively, with an excitation wavelength
at 295 nm; this band is due to the presence of tryptophans,
i.e. the tryptophan at position 214 in HSA and the tryptophans
at positions 134 and 212 in BSA.50
The quenching in the fluorescence emission spectra of the
SAs induced by the presence of the complexes was low for the
complexes in the case of HSA (the quenching of the initial HSA
fluorescence emission (DI/I0) reached B49.3% in the presence
of complex 3, Fig. 6A) and was much more pronounced for BSA
(the quenching of the initial BSA fluorescence emission (DI/I0)
reached 74.8% in the presence of complex 2, Fig. 6B). This
quenching of the SA fluorescence emission band may be
ascribed to possible changes in the tryptophan environment
of SA and, subsequently, changes in the secondary structure of
albumin arising from the binding of each complex to SA.53a
The quenching constants (kq) of the interactions of the
complexes with the albumins were calculated (Table 3) from
the corresponding Stern–Volmer plots (Fig. S9 and S10, ESI†)
and Stern–Volmer quenching equation (eqn (S2) and (S3),
ESI†), where the fluorescence lifetime of tryptophan in SA
was taken as t0 = 10
8 s;52 the quenching constants are
significantly higher than the value of 1010 M1 s1, suggesting
that the interaction of the complexes with the albumins takes
place via a static quenching mechanism,52 which indicates the
formation of a new conjugate between each complex and the
albumin. The kq constants of complexes 1–4 may show signifi-
cant SA-quenching ability for the complexes; this effect was
more intense in the case of BSA, with complex 1 showing the
highest kq for HSA and complex 2 for BSA. The derived kq
constants for complexes 1–4 are within the range found for a series
of metal-complexes bearing NSAIDs as ligands.17,22,29–33,65–69
The SA-binding constants (K) of the complexes have been
determined (Table 3) from the corresponding Scatchard plots
(Fig. S11 and S12, ESI†) and the Scatchard equation (eqn (S4),
ESI†). The K constants of complexes 1–4 are all relatively high,
similar to their respective free NSAIDs, and are in the range of
the values calculated for metal–NSAID complexes.17,22,29–33,65–69
Among the present complexes, complexes 4 and 1 bear the
highest K constants for HSA and BSA, respectively. Considering
the structural factors present in complexes 1–4, it seems that
complexes 1 and 2 bearing Z6-p-cymene ligands show higher
binding activity for BSA than their analogues 3 and 4 bearing
Z6-toluene ligands. In the case of HSA, we cannot confidently
suggest a structural factor that leads to higher binding affinity.
The SA-binding constants of complexes 1–4 lie in the range
of 4.24  104 to 4.49  105 M1 (Table 3) and are high enough
to reveal the potential binding of the complexes to SAs in order
to enable transfer towards potential biotargets. Additionally,
the K constants are significantly lower than the value of 1015 M1,
i.e. the binding constant of avidin with diverse compounds,74
which is the strongest known non-covalent reversible interaction;53c
this comparisonmay indicate reversible binding of the complexes to
the SAs and may reveal the potential for release upon arrival at the
desired target.
Interaction of the complexes with CT DNA. Covalent binding
or noncovalent interactions are the most common interactions
between metal complexes and double-stranded DNA. Covalent
binding takes place when nitrogen atoms of DNA-bases
displace one or more labile ligands of the complex, while
the noncovalent interactions are: (i) intercalation, i.e. p-p
stacking interactions between the complex and DNA nucleobases,
(ii) electrostatic interactions, namely Coulomb forces developed
between the complexes and the phosphate groups of DNA, and
(iii) groove-binding, attributed to van der Waals or hydrogen-
bonding or hydrophobic bonding interactions along the grooves
of the DNA helix.75a The potential anticancer and/or anti-
inflammatory activities of NSAIDs and their complexes are often
related to their DNA-binding behavior.17,75b Within this context,
Fig. 6 (A) Plot of relative HSA fluorescence intensity at lem = 352 nm
(I/I0, %) vs. r (r = [complex]/[HSA]) for complexes 1–4 (up to 54.1% of the
initial HSA fluorescence for 1, 50.7% for 2, 80.7% for 3 and 52.0% for 4) in
buffer solution (150 mM NaCl and 15 mM trisodium citrate at pH 7.0).
(B) Plot of relative BSA fluorescence intensity at lem = 343 nm (I/I0, %) vs.
r (r = [complex]/[BSA]) for complexes 1–4 (up to 28.2% of the initial BSA
fluorescence for 1, 25.2% for 2, 52.8% for 3 and 29.0% for 4) in buffer
solution (150 mM NaCl and 15 mM trisodium citrate at pH 7.0).
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the DNA-binding affinities of complexes 1–4 were studied in vitro
by UV-vis spectroscopy, viscosity measurements and their ability
to displace the typical DNA-intercalator EB.
UV-vis spectroscopy is used as a preliminary method to
examine the DNA-binding mode and to calculate its strength.
Any changes observed in the DNA-band or the intraligand
transition bands of the complexes may reveal the existence of
interactions and their possible modes. The UV-vis spectra of a
CT DNA solution in the presence of complex 4 at increasing
r values are shown representatively in Fig. 7A. The band at
lmax = 258 nm exhibits a slight hypochromism accompanied by
a red-shift up to 260 nm, suggesting the existence of interactions
between CT DNA and the complex leading to the formation of a
new complex-DNA conjugate76 and resulting in stabilization of the
CT DNA double-helix.77 The behaviour of CT DNA in the presence
of the other complexes is quite similar.
In the UV-vis spectra of complex 1 (Fig. 7B), the intraligand
band observed at 321 nm exhibited in the presence of CT DNA
showed slight hypochromism of up to 7%. Similar changes
were observed in the UV-vis spectra of complex 3 in the
presence of DNA (Table 4). In the UV-vis spectra of complex 4
(Fig. 7C), upon addition of CT DNA, the intraligand band
located at 282 nm (I) presented a significant hyperchromism
up to 20% followed by a significant red-shift of 15 nm; upon
addition of CT DNA, the second band located at 349 nm (II)
presented an intense hypochromism up to 50% followed by
elimination. Similar spectroscopic features were observed in
the UV-vis spectra of complex 2 in the presence of DNA
(Table 4). Safe conclusions cannot be merely derived from
UV-vis spectroscopic titration studies. Of course, the significant
percentage of hypochromism observed for the mefenamato
complexes 2 and 4 can be attributed to p-p stacking interactions
between the aromatic chromophores of the complexes and DNA-
bases53b,c and may be consistent with an intercalative binding
mode, leading to stabilization of the DNA helix.77 However, in
order to clarify the DNA-binding modes of complexes 1–4, DNA-
viscosity measurements were performed.
The DNA-binding constants (Kb) of complexes 1–4 (Table 4)
were calculated using the Wolfe–Shimer equation53a (eqn (S5),
ESI†) and the corresponding plots of [DNA]/(eA  ef) versus
[DNA] (Fig. S13, ESI†). The Kb constants of complexes 1–4
(Table 4) are relatively high and suggest strong binding of
the complexes to CT DNA. Considering the structural factors
present in complexes 1–4, it seems that the complexes bearing
Z6-p-cymene ligands (1 and 2) show higher DNA-affinity than
their analogues bearing Z6-toluene ligands (3 and 4); also, the
complexes bearing mefenamato ligands (2 and 4) are better
Table 3 The albumin quenching and binding constants for complexes 1–4
Compound kq(HSA) (M
1 s1) K(HSA) (M
1) kq(BSA) (M
1 s1) K(BSA) (M
1)
Hindo22 7.80(0.60)  1012 2.22(0.19)  105 7.68(0.28)  1012 8.95(0.40)  105
Hmef30 7.13(0.34)  1012 1.32(0.15)  105 2.78(0.20)  1013 1.35(0.22)  105
1 6.10(0.29)  1012 2.15(0.08)  105 1.25(0.05)  1013 4.49(0.30)  105
2 5.46(0.19)  1012 9.79(0.34)  104 1.70(0.08)  1013 3.63(0.15)  105
3 2.04(0.13)  1012 9.44(0.40)  104 4.85(0.11)  1012 5.30(0.18)  104
4 4.32(0.29)  1012 4.24(0.12)  105 1.30(0.04)  1013 2.63(0.10)  105
Fig. 7 (A) UV-vis spectra of CT DNA (0.175 mM) in buffer solution (150 mM
NaCl and 15 mM trisodium citrate at pH 7.0) in the absence or presence of
complex 4. (Inset: Enlargement of the circled area.) The arrows show the
changes upon addition of increasing amounts of the complex. (B and C) UV-vis
spectra of DMSO solutions of complex (B) 1 (0.1 mM) and (C) 4 (0.1 mM) in the
presence of increasing amounts of CT DNA (r0 = [DNA]/[compound] = 0 to 0.8).
The arrows show the changes upon addition of increasing amounts of CT DNA.
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DNA-binders than those bearing indomethacin ligands (1 and 3),
with complex 2 having the highest Kb constant (3.69(0.40) 
105 M1) among the complexes. The Kb constants of complexes
1–4 are within the range found for other metal–NSAID
complexes.17,22,29–33,65–69 Further, the Kb constants are similar
to or higher than that of the classical intercalator EB (1.23 
105 M1) as calculated by Dimitrakopoulou et al.78
The interaction of complexes 1–4 with CT DNA was also
monitored via DNA-viscosity measurements in the presence of
increasing amounts of the complexes. As is known, the relative
DNA-viscosity (Z/Z0) is sensitive to relative DNA-length changes
(L/L0) occurring in the presence of a DNA-binder because they
are correlated by the equation L/L0 = (Z/Z0)
1/3.79 In the case of
intercalation, the DNA-viscosity will increase, while in the case
of non-classical intercalation, i.e. groove-binding or electro-
static interaction, the DNA-viscosity may decrease slightly or
remain unchanged.
The changes in the viscosity of a CT DNA solution (0.1 mM)
were studied in the presence of increasing amounts of
complexes 1–4 (up to the value of r = 0.35). For all complexes,
the DNA-viscosity showed a considerable increase upon their
addition (Fig. 8). This increase may be attributed to inter-
calation of the complexes between DNA-bases because in the
case of intercalation, the separation distance of the DNA bases
will increase in order to accommodate the intercalating
compounds and, subsequently, the DNA-viscosity will increase.79
The existing conclusion of intercalation may clarify and enforce
the preliminary conclusions derived from the UV-vis spectroscopic
studies.
EB is a typical DNA-intercalator; its intercalation between
DNA-bases via its planar phenanthridine ring results in the
formation of the EB–DNA conjugate, which exhibits an intense
fluorescence emission band at 592 nm with lex = 540 nm. The
displacement of EB from the EB–DNA conjugate induced by a
compound that can intercalate DNA may indirectly verify the
intercalating ability of the compound. In such a case, quenching
of the EB–DNA fluorescence emission band will appear upon
addition of the DNA-intercalating compound.51,55a
The EB–DNA conjugate was completely formed after pre-
treatment of EB ([EB] = 20 mM) and DNA ([DNA] = 26 mM) for 1 h
in buffer solution. The fluorescence emission spectra of the
EB–DNA conjugate were recorded for increasing amounts of the
Table 4 UV-vis spectral features of the interaction of complexes 1–4
with CT DNA. UV-band (l in nm) (percentage of the observed hyper-/
hypo-chromism (DA/A0, %), blue-/red-shift of the lmax (Dl, nm)) and
DNA-binding constants (Kb)
Compound Band (DA/A0,
a Dlb) Kb (M
1)
Hindo17 314 (sh) (10, 0) 3.37(0.23)  105
Hmef28 324 (+10, 0) 1.05(0.02)  105
1 321 (7, 0) 2.85(0.17)  105
2 296 (4+40, +12); 350 (50, elmc) 3.69(0.40)  105
3 321 (3, 0) 3.24(0.22)  104
4 282 (+20, +15); 349 (50, elm)b,c 3.15(0.12)  105
a ‘‘+’’ denotes hyperchromism, ‘‘–’’ denotes hypochromism. b ‘‘+’’
denotes red-shift, ‘‘–’’ denotes blue-shift. c ‘‘elm’’ = eliminated.
Fig. 8 Relative viscosity (Z/Z0)
1/3 of CT DNA (0.1 mM) in buffer solution
(150 mM NaCl and 15 mM trisodium citrate at pH 7.0) in the presence of
increasing amounts of complexes 1–4 (r = [complex]/[DNA]).
Fig. 9 (A) Fluorescence emission spectra (lexc = 540 nm) for EB–DNA
([EB] = 20 mM, [DNA] = 26 mM) in buffer solution in the absence and
presence of increasing amounts of complex 2 (up to the value of r = 0.35).
The arrow shows the changes of intensity upon increasing amounts of 2.
(B) Plot of the relative fluorescence intensity of EB–DNA (%I/I0) at
lem = 592 nm vs. r (r = [complex]/[DNA]) in buffer solution (150 mM NaCl
and 15 mM trisodium citrate at pH 7.0) in the presence of complexes 1–4
(quenching up to 18.5% of the initial EB–DNA fluorescence for 1, 11.3%
for 2, 27.5% for 3 and 18.5% for 4).
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compounds (representatively shown for complex 2 in Fig. 9A up
to r = 0.35). The complexes under study did not show any
appreciable fluorescence emission bands at room temperature
in solution or in the presence of EB or CT DNA under the same
experimental conditions, i.e. with lex = 540 nm. Therefore,
the observed quenching upon addition of complexes 1–4 is
significant (up to 88.7% of the initial EB–DNA fluorescence
emission intensity, Table 5 and Fig. 9B) and can be attributed
to the displacement of EB from the EB–DNA conjugate and its
replacement by the complexes; thus, binding of the complexes
at the DNA-intercalation sites may be indirectly concluded.51
The quenching of the EB–DNA fluorescence is in good
agreement with the linear Stern–Volmer equation (eqn (S2),
ESI†),53 as shown in the corresponding Stern–Volmer plots
(R B 0.99, Fig. S14, ESI†). The KSV constants of the complexes
(Table 5) are in the range reported for other metal–NSAID
complexes,17,22,29–33,65–69 with complex 1 having the highest
KSV constant among the complexes. The quenching constants
of the compounds (kq) in regard to their competition with EB
were calculated according to eqn (S3) (ESI†), where the fluores-
cence lifetime of the EB–DNA system has the value t0 = 23 ns.
55b
The derived kq constants (Table 5) are significantly higher than
1010 M1 s1, suggesting that the quenching of the EB–DNA
fluorescence by the complexes takes place via a static mechanism
which leads to the formation of a new conjugate, obviously
between DNA and each complex.51
Conclusions
The paper presented here showed that two chosen NSAIDs,
HIndo and HMef, in the reaction with Ru(II)–arene complexes
were bound monodentately via a carboxylate group. This was
confirmed by NMR and IR spectroscopy results as well as by
mass spectrometry.
Cytotoxicity studies revealed that the NSAIDs ligand Hindo,
despite having poor activity itself, when coordinated to
ruthenium(II)–arenes such as 1 and 3, enhanced the cytotoxicity
of the resulting complexes; meanwhile, the p-bonded arenes
p-cymene (1) and toluene (2) did not seem to impact the in vitro
cytotoxic potential of the complexes. A study of the mechan-
isms of action in CDDP resistant breast carcinoma MDA-MB-
231 cells, using flow cytometry, revealed that complexes 1 and 3
arrested the cell cycle in S phase and caused rapid DNA-
fragmentation and accumulation in sub-G1 phase. Even more
than 40% of cells underwent either apoptotic or necrotic cell
death after 24 h action of 1 and 3 at IC50. Hindo certainly
provided features that improved the cytotoxic activity of the
resulting complexes 1 and 3. Intercalation may be the most
likely mode of interaction with DNA, as revealed by in vitro
DNA-viscosity experiments with CT-DNA and EB-displacement
experiments. The indomethacin-ruthenium complexes are better
‘‘DNA-binders’’ than the corresponding free indomethacin ligands.
Additionally, fragmentation of DNA may be partially caused by
indirect pathways, such as ROS production. Measurements of
intracellular ROS production in MDA-MB-231 cells after 4 h of
treatment with 1 and 3 at IC50 showed increased ROS levels,
suggesting that the complexes exhibit multiple-layer cytotoxic
effects that are also triggered by ROS release. The biological
actions of most NSAIDs, including Hindo, customarily involve
selective inhibition of cyclooxygenases (COX-1 and COX-2).80,81
However, literature data provide evidence that the pharmaco-
kinetic properties of NSAIDs may be also related to their ability
to interact with membrane phospholipids and/or to disrupt
membrane permeability, suggesting that effects at the cell
membrane level may be an additional mechanism of action
and toxicity of ruthenium-indomethacin complexes 1 and 3.82
In the present study, complexes 1–4 were also tested in regard to
their ability to scavenge DPPH, ABTS and hydroxyl radicals,
to inhibit soybean lipoxygenase activity and to bind to serum
albumins. The results showed that, in general, the complexes are
more active radical scavengers and LOX inhibitors than their
corresponding free NSAIDs. The interaction of the complexes
with albumins showed their potential ability to bind tightly and
reversibly to albumins, enabling them to be transferred to and
released at their potential biological targets.
In the expanding field of rational drug discovery, ruthenium
complexes represent a promising class of small molecules that
can be optimized to more specifically target tumour cells. The
results of the present study of ruthenium(II)–arene complexes
conjugated to indomethacin contribute to the development of
so-called ‘‘combi-molecules’’ that may exhibit stronger or more
specific antitumor effects than their single complexes or ligands
alone. The present results may be considered to be promising for
further biological studies and potential applications.
Abbreviations
K562 Human myelogenous leukemia cells
A549 Human lung adenocarcinoma cells
MDA-MB-231 Human breast adenocarcinoma cells
MRC-5 Non-tumor human lung fibroblast cells
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide dye
RPMI 1640 Roswell Park Memorial Institute nutrient
medium (1640)
CDDP cis-Diamminedichloridoplatinum(II),
cisplatin
DCFH-DA 20,70-Dichlorodihydrofluorescein
diacetate
DNA Deoxyribonucleic acid
Table 5 Percentage of EB–DNA fluorescence quenching (DI/I0, %),
Stern–Volmer constants (KSV) and quenching constants of EB–DNA
fluorescence (kq) for complexes 1–4
Compound DI/I0 (%) KSV (M
1) kq (M
1 s1)
Hindo22 87.5 3.62(0.09)  105 1.57(0.04)  1013
Hmef30 80.0 1.58(0.06)  105 6.87(0.26)  1012
1 81.5 8.96(0.30)  104 3.90(0.13)  1012
2 88.7 7.71(0.26)  104 3.35(0.12)  1012
3 72.5 3.75(0.13)  104 1.63(0.06)  1012
4 81.5 6.67(0.23)  104 2.90(0.10)  1012
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ROS Reactive oxygen species
KP1019 Indazolium-trans-tetrachlorobis-
(1H-indazole)ruthenate(III)
KP1339 Sodium-trans-tetrachlorobis-
(1H-indazole)ruthenate(III)
NAMI Sodium-trans-
imidazoledimethylsulfoxidetetrachloro-
ruthenate(III)
TrxR Thioredoxin
NSAID Non-steroidal anti-inflammatory drug
COX Enzyme cyclooxygenase
Hindo Indomethacin
Hmef Mefenamic acid
DPPH 1,1-Diphenyl-picrylhydrazyl
ABTS+ 2,20-Azinobis-(3-ethylbenzothiazoline-
6-sulfonic acid) radicals
LOX Soybean lipoxygenase
BSA Bovine serum albumin
HSA Human serum albumin
CT DNA Calf-thymus deoxyribonucleic acid
UV-vis spectroscopy Ultraviolet-visible spectroscopy
EB Ethidium bromide
ABTS 2,20-Azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid)
BHT Butylated hydroxytoluene
Trolox 6-Hydroxy-2,5,7,8-tetramethylchromane-
2-carboxylic acid
NDGA Nordihydroguaiaretic acid
HEPES 4-(2-Hydroxyethyl)piperazine-
1-ethanesulfonic acid
FCS Fetal calf serum
DMSO Dimethyl sulfoxide
PBS Phosphate buffer solution
PI Propidium iodide
RNaseA Ribonuclease A
NDGA 4,40-(2,3-Dimethylbutane-
1,4-diyl)dibenzene-1,2-diol
(nordihydroguaiaretic acid)
BHT Butylated hydroxytoluene
(2,6-di-tert-butyl-4-methylphenol)
EDTA Ethylendiaminetetraacetic acid
SA Serum albumin
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